Taysha Gene Therapies
Taysha Gene Therapies
TSHA
NASDAQ
2.24
USD
40.88%
About
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder.
The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome.
It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 916.5K |
| Three Month Average Volume | 51.8M |
| High Low | |
| Fifty-Two Week High | 4.32 USD |
| Fifty-Two Week Low | 1.27 USD |
| Fifty-Two Week High Date | 13 Jun 2024 |
| Fifty-Two Week Low Date | 14 Nov 2023 |
| Price and Volume | |
| Current Price | 2.24 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | 0.97% |
| Thirteen Week Relative Price Change | -38.98% |
| Twenty-Six Week Relative Price Change | -36.93% |
| Fifty-Two Week Relative Price Change | -44.14% |
| Year-to-Date Relative Price Change | 6.87% |
| Price Change | |
| One Day Price Change | 4.19% |
| Thirteen Week Price Change | -34.69% |
| Twenty-Six Week Price Change | -30.65% |
| Five Day Price Change | 1.82% |
| Fifty-Two Week Price Change | -30.00% |
| Year-to-Date Price Change | 26.55% |
| Month-to-Date Price Change | 1.36% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.40082 USD |
| Book Value Per Share (Most Recent Quarter) | 0.54061 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.40082 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.54061 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.37824 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.13306 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.06434 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.96077 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.89871 USD |
| Normalized (Last Fiscal Year) | -0.93956 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.96077 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.89871 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.96077 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.89871 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.7699 USD |
| Cash Per Share (Most Recent Quarter) | 0.85779 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.94871 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.56453 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.37846 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -588 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -888.18% |
| Pretax Margin (Last Fiscal Year) | -722.06% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -477.88% |
| Operating Margin (Trailing Twelve Months) | -617.75% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -722.06% |
| Net Profit Margin (Trailing Twelve Months) | -888.18% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -53.57% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 34.05% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 76.52% |
| EPS Change (Trailing Twelve Months) | 60.85% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 6 |
| Price to Tangible Book (Most Recent Quarter) | 4 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -134,537,000 |
| Net Debt (Last Fiscal Year) | -103,078,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 30 |
| Price to Sales (Trailing Twelve Months) | 36 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 6 |
| Price to Book (Most Recent Quarter) | 4 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 54 |
| Long Term Debt to Equity (Most Recent Quarter) | 35 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -76,887,000 |
| Free Cash Flow (Trailing Twelve Months) | -75,726,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -50 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 55 |
| Total Debt to Equity (Most Recent Quarter) | 35 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -74.62% |
| Return on Assets (Trailing Twelve Months) | -81.11% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -294.04% |
| Return on Equity (Trailing Twelve Months) | -318.69% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -111.87% |
| Return on Investment (Trailing Twelve Months) | -116.01% |
| Return on Investment (5 Year) | -99,999.99% |